Navigation Links
Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Date:2/7/2011

ration will help Optimer realize the full potential of fidaxomicin and will help position this medication in these countries as the first line of treatment, both for treating CDI and reducing recurrences," said Pedro Lichtinger, Optimer's President and CEO.  "CDI poses a significant cost burden on the healthcare system and we believe, if approved, fidaxomicin will provide a cost-savings opportunity for hospitals and payers, especially when used in populations at risk of recurrence such as the elderly, patients with a prior episode, those taking concomitant antibiotics, immuno compromised patients or those with renal impairment."

Fidaxomicin is an orally administered macrocyclic antibiotic with a new mechanism and narrow spectrum of action being developed for the treatment of CDI. In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  Most importantly, fidaxomicin was statistically superior to vancomycin in global cure and in reducing recurrences of CDI by up to 47%. The New England Journal of Medicine has published results from the first Phase 3 trial in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," which appeared in the February 3, 2011 issue.  Optimer has filed marketing applications in the U.S. and the EU for fidaxomicin.  

Optimer's exclusive financial advisor for this transaction was J.P. Morgan Securities LLC while Cooley LLP was its legal advisor.  Astellas' legal advisor in the transaction was Wragge & Co LLP.

Scheduled Conference CallOptimer will host a conference call today at 6:00 a.m. Pacific Time (9:00 p.m. Eastern Time) to discuss this announcement.  To participate in the conference call, please dial (877) 280-7280 from the U.S., or (678) 825-8232 for international callers.  Please specify to the operator that you wou
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Wrightington, Wigan ... Allscripts (NASDAQ: MDRX ) are delighted to ... as WWL,s new health information system. The system will ... completely transform the way WWL delivers healthcare in the ... a demonstrated record of on-time and on-budget system implementations ...
(Date:9/30/2014)... 30, 2014 This study provides an ... informatics solutions including nuclear imaging informatics, PET imaging ... study assesses the size of the market based ... and projects future growth based on the current ... taking place in the broader markets for imaging ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group ... in Brazil , Russia ... China (BRIC) will see robust expansion ... increasingly favored over surgical procedures. Although revenues will be ... reimbursement challenges, prolonged device approval times and demand for ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... Feb. 23, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Department of Defense (DOD) to provide remote service and support ... the DOD,s secure B2B gateway. Roche is the first in-vitro ... for this remote access. The B2B gateway is ...
... Feb. 23, 2011 Xenogenics Corporation ("Xenogenics"), a majority ... MCET), is pleased to announce it has retained the ... of its capital formation strategy to help finance expanded ... In animal testing and initial human use, the ...
Cached Medicine Technology:Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD 2Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 2Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 3Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts 4
(Date:10/1/2014)... October 01, 2014 QueenBeeTickets.com is giving music ... the singer’s upcoming North American tour, which has him traveling ... come. , Click here to view the selection ... performer’s newest album, is due to come out on October ... shortly thereafter. Bob Seger concert tickets are available for shows ...
(Date:9/30/2014)... medical and nursing students in developing countries may have ... graduation, while less than one fifth of them intend ... most, according to a new study. , Health workforce ... outbreak of Ebola in western Africa. The disease initially ... world,s poorest countries (Guinea, Sierra Leone and Liberia), where ...
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. ... tend to put the brakes on motherhood. And for many ... permanent choice, new research suggests. Women in their early ... child during tough economic times. But, according to the new ... into their 40s and beyond. The findings suggest that ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Sleep apnea is a potential health ... to a possible culprit behind the disorder: a "fat" tongue. ... deposits are increased in the tongue of obese patients with ... of the Sleep Center at the University of Pennsylvania Medical ... which will publish the findings Oct. 1. Sleep apnea ...
(Date:9/30/2014)... slow the spiraling costs of drugs paid for by ... no meaningful impact on cancer chemotherapy drug costs, say ... Clinical Oncology published online today. , "We looked ... lung cancers, and did not find a substantial change ... of the recent Medicare law in 2005," says the ...
Breaking Medicine News(10 mins):Health News:Bob Seger Presale Tickets: QueenBeeTickets.com Delights Fans with Discounted Tickets for All 20 Stops on Seger’s “Ride Out” Tour with The Silver Bullet Band 2Health News:Developing countries should enroll medical and nursing students from rural areas 2Health News:Developing countries should enroll medical and nursing students from rural areas 3Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2
... Singh Saini might not enter the Guinness Book of World ... exam at the age// of 11 definitely makes her a ... of Dhanpat Singh Saini, a medical practitioner, passed her Class ... of Mangalam Vidhyapeeth School in the Basbadanpura area of this ...
... Commissioner of Prevention, Department of Health, Union government, held ... Thursday// to prepare for mass vaccination of children to ... is proposed from May 15 to May 30 and ... be covered during the drive. ,Biswal while ...
... the US National Cancer Institute in Bethesda, Maryland, and Jaakko ... that it is waste of time and money to search ... in the British Medical Journal. They say that there is ... lump of money is being invested. Researchers believe that if ...
... an ultra-modern medical college and hospital in his home district of ... Mata Janki Kunwar Hospital in Bettiah to a full-fledged medical college ... the development path. ,"I would love to help and ensure ... a visit here Friday. ,Jha's announcement has come at ...
... is awarded the Australian Mother of the Year. She is the ... philanthropist working for the welfare// of many who are in need. ... , This was in lieu of the Mother's Day celebration held ... has devoted 15 years of her entire life for serving disabled ...
... conducted in Madhya Pradesh has stated that more than 70 ... a part of curriculum in schools//. ,The Madhya Pradesh ... age group 10 to 19 years in 12 districts of ... education, saying the awareness would help them remain healthy and ...
Cached Medicine News:Health News:Jaipur Girl’s Rare Feat: The Youngest To Pass Class 12 At The Age Of 1 2Health News:The Department of Health Gears Up To The Arrival Of JE Vaccines 2Health News:Girls In MP Want Sex Education In Schools: Health Survey 2
Portable shields for your safety and convenience....
Provide 1.5mm protection throughout. Six durable, attractive vinyl coverings are available. Lead glass window factory installed. Larger window available....
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr...
Front Protection with attached Belt Guard, Built-in Back Support; Buckle Closure...
Medicine Products: